Antisense Therapeutics Limited Stock Today
| ATHJF Stock | USD 0.04 0.00 0.00% |
Performance9 of 100
| Odds Of DistressLess than 38
|
Antisense Therapeutics is trading at 0.042 as of the 30th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.042. Antisense Therapeutics has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Antisense Therapeutics Limited are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.. The company has 669.04 M outstanding shares. More on Antisense Therapeutics Limited
Moving against Antisense Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Antisense Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Antisense Therapeutics Limited [ATHJF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Antisense Therapeutics's market, we take the total number of its shares issued and multiply it by Antisense Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Antisense Therapeutics classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 669.04 M outstanding shares.
Antisense Therapeutics Limited has accumulated about 19.23 M in cash with (7.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03.
Check Antisense Therapeutics Probability Of Bankruptcy
Ownership AllocationAntisense Therapeutics holds a total of 669.04 Million outstanding shares. Antisense Therapeutics Limited shows 19.3 percent of its outstanding shares held by insiders and 4.93 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Antisense Ownership Details
Antisense Therapeutics Risk Profiles
| Mean Deviation | 9.72 | |||
| Standard Deviation | 39.12 | |||
| Variance | 1530.04 | |||
| Risk Adjusted Performance | 0.0993 |
Antisense Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Antisense Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Other Information on Investing in Antisense Pink Sheet
Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.